Last reviewed · How we verify

Akkermansia muciniphila + Infliximab

Chinese Medical Association · FDA-approved active Small molecule

Akkermansia muciniphila + Infliximab is a Combination therapy: probiotic + TNF-α inhibitor Small molecule drug developed by Chinese Medical Association. It is currently FDA-approved for Inflammatory bowel disease (Crohn's disease or ulcerative colitis), Microbiota-associated inflammatory conditions.

A combination therapy that uses the probiotic bacterium Akkermansia muciniphila to restore gut microbiota balance while infliximab suppresses TNF-α-mediated inflammation.

A combination therapy that uses the probiotic bacterium Akkermansia muciniphila to restore gut microbiota balance while infliximab suppresses TNF-α-mediated inflammation. Used for Inflammatory bowel disease (Crohn's disease or ulcerative colitis), Microbiota-associated inflammatory conditions.

At a glance

Generic nameAkkermansia muciniphila + Infliximab
SponsorChinese Medical Association
Drug classCombination therapy: probiotic + TNF-α inhibitor
TargetTNF-α (infliximab component); gut microbiota modulation (Akkermansia muciniphila component)
ModalitySmall molecule
Therapeutic areaImmunology / Gastroenterology
PhaseFDA-approved

Mechanism of action

Akkermansia muciniphila is a commensal bacterium that strengthens intestinal barrier function and promotes anti-inflammatory immune responses. Infliximab is a TNF-α inhibitor that reduces systemic inflammation. Together, they aim to restore dysbiotic microbiota and reduce inflammatory pathways implicated in inflammatory bowel disease and related conditions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Akkermansia muciniphila + Infliximab

What is Akkermansia muciniphila + Infliximab?

Akkermansia muciniphila + Infliximab is a Combination therapy: probiotic + TNF-α inhibitor drug developed by Chinese Medical Association, indicated for Inflammatory bowel disease (Crohn's disease or ulcerative colitis), Microbiota-associated inflammatory conditions.

How does Akkermansia muciniphila + Infliximab work?

A combination therapy that uses the probiotic bacterium Akkermansia muciniphila to restore gut microbiota balance while infliximab suppresses TNF-α-mediated inflammation.

What is Akkermansia muciniphila + Infliximab used for?

Akkermansia muciniphila + Infliximab is indicated for Inflammatory bowel disease (Crohn's disease or ulcerative colitis), Microbiota-associated inflammatory conditions.

Who makes Akkermansia muciniphila + Infliximab?

Akkermansia muciniphila + Infliximab is developed and marketed by Chinese Medical Association (see full Chinese Medical Association pipeline at /company/chinese-medical-association).

What drug class is Akkermansia muciniphila + Infliximab in?

Akkermansia muciniphila + Infliximab belongs to the Combination therapy: probiotic + TNF-α inhibitor class. See all Combination therapy: probiotic + TNF-α inhibitor drugs at /class/combination-therapy-probiotic-tnf-inhibitor.

What development phase is Akkermansia muciniphila + Infliximab in?

Akkermansia muciniphila + Infliximab is FDA-approved (marketed).

What are the side effects of Akkermansia muciniphila + Infliximab?

Common side effects of Akkermansia muciniphila + Infliximab include Infection (bacterial, viral, fungal), Infusion reactions, Gastrointestinal disturbances, Headache, Immunosuppression-related complications.

What does Akkermansia muciniphila + Infliximab target?

Akkermansia muciniphila + Infliximab targets TNF-α (infliximab component); gut microbiota modulation (Akkermansia muciniphila component) and is a Combination therapy: probiotic + TNF-α inhibitor.

Related